Illumina Beats Q2 Estimates, Lifts 2026 Outlook on Strong NovaSeq X Demand
ILMN has more than doubled off its 52-week low of $88.
Summary
Illumina delivered a clean beat-and-raise quarter. Q2 revenue of $1.16B topped the $1.13B consensus, and adjusted EPS of $1.31 beat by $0.08. Management raised full-year 2026 revenue guidance to $4.60-$4.64B (from $4.52-$4.62B) and non-GAAP EPS to $5.30-$5.40 (from $5.15-$5.30), citing strong NovaSeq X demand and clinical customer expansion. Rest-of-world organic growth ex-China accelerated to 8.1%, and the company now expects ROW growth above 5% for the year, up from 2%-4%. This follows a period of heavy insider selling by Director Keith Meister, but the operational momentum and raised guidance directly counter any demand concerns. The stock is trading near its 52-week high, and the guidance raise supports the premium multiple.
At the time of this announcement, ILMN was trading at $213.00 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $31B. The 52-week trading range was $88.00 to $205.47. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Reuters.